Detalhe da pesquisa
1.
Antibodies against endogenous retroviruses promote lung cancer immunotherapy.
Nature
; 616(7957): 563-573, 2023 04.
Artigo
Inglês
| MEDLINE | ID: mdl-37046094
2.
Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.
N Engl J Med
; 390(2): 118-131, 2024 Jan 11.
Artigo
Inglês
| MEDLINE | ID: mdl-38197815
3.
Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions.
N Engl J Med
; 389(22): 2039-2051, 2023 Nov 30.
Artigo
Inglês
| MEDLINE | ID: mdl-37870976
4.
Publisher Correction: The National Lung Matrix Trial of personalized therapy in lung cancer.
Nature
; 585(7826): E21, 2020 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-32887973
5.
The National Lung Matrix Trial of personalized therapy in lung cancer.
Nature
; 583(7818): 807-812, 2020 07.
Artigo
Inglês
| MEDLINE | ID: mdl-32669708
6.
Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC-ESTRO OligoCare consortium.
Lancet Oncol
; 24(3): e121-e132, 2023 03.
Artigo
Inglês
| MEDLINE | ID: mdl-36858728
7.
The Cancer Research UK Stratified Medicine Programme as a model for delivering personalised cancer care.
Br J Cancer
; 128(2): 161-164, 2023 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36599918
8.
Hyperglycaemia following immune checkpoint inhibitor therapy-Incidence, aetiology and assessment.
Diabet Med
; 40(4): e15053, 2023 04.
Artigo
Inglês
| MEDLINE | ID: mdl-36696014
9.
Health Utility Analysis of Tepotinib in Patients With Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping.
Value Health
; 26(8): 1155-1163, 2023 08.
Artigo
Inglês
| MEDLINE | ID: mdl-36805576
10.
Updates in Management of Malignant Pleural Mesothelioma.
Curr Treat Options Oncol
; 24(12): 1758-1789, 2023 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-37975977
11.
EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study.
Lancet Oncol
; 23(6): 758-767, 2022 06.
Artigo
Inglês
| MEDLINE | ID: mdl-35588752
12.
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.
Lancet
; 397(10272): 375-386, 2021 01 30.
Artigo
Inglês
| MEDLINE | ID: mdl-33485464
13.
Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG).
Oncologist
; 27(4): 255-265, 2022 04 05.
Artigo
Inglês
| MEDLINE | ID: mdl-35274704
14.
Indirect comparisons of brigatinib and alectinib for front-line ALK-positive non-small-cell lung cancer.
Future Oncol
; 18(20): 2499-2510, 2022 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-35608148
15.
Large cell neuroendocrine lung carcinoma: consensus statement from The British Thoracic Oncology Group and the Association of Pulmonary Pathologists.
Br J Cancer
; 125(9): 1210-1216, 2021 10.
Artigo
Inglês
| MEDLINE | ID: mdl-34489586
16.
Navigating Diagnostic and Treatment Decisions in Non-Small Cell Lung Cancer: Expert Commentary on the Multidisciplinary Team Approach.
Oncologist
; 26(2): e306-e315, 2021 02.
Artigo
Inglês
| MEDLINE | ID: mdl-33145902
17.
Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.
N Engl J Med
; 379(21): 2027-2039, 2018 11 22.
Artigo
Inglês
| MEDLINE | ID: mdl-30280657
18.
Mucinous adenocarcinoma arising in congenital pulmonary airway malformation: clinicopathological analysis of 37 cases.
Histopathology
; 78(3): 434-444, 2021 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-32810914
19.
Brigatinib vs alectinib in crizotinib-resistant advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALTA-3).
Future Oncol
; 17(32): 4237-4247, 2021 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-34423676
20.
Presence of pleomorphic features but not growth patterns improves prognostic stratification of epithelioid malignant pleural mesothelioma by 2-tier nuclear grade.
Histopathology
; 77(3): 423-436, 2020 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-32333813